Life Sciences Opportunities in India & China: From Innovation to Commercialization
30 September 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
17 July 2024
Viewpoints
New York Department of Financial Services Issues New Guidance Concerning the Use of Artificial Intelligence in Insurance– What You Need to Know
On July 11, 2024, the New York Department of Financial Services issued Insurance Circular Letter No. 7 adopting guidance regarding the use of artificial intelligence in underwriting and pricing decisions.
17 July 2024
Innovative Technology Insights
USPTO Clarifies Patent-Eligibility Guidelines for AI Inventions
Effective July 17, 2024 the USPTO has provided an update to its 2019 guidance on patent eligibility for AI innovations.
17 July 2024
Viewpoints
Five Compliance Best Practices Every Multinational Company Should Consider for … Drafting or Updating a Global Code of Conduct
Drafting a global code of conduct is a critical step in establishing a comprehensive framework for ethical behavior and compliance across an organization’s global operations.